Intellipharmaceutics International Inc. Securities Litigation

If you purchased a significant amount of shares of Intellipharmaceutics International Inc. (NASDAQ: IPCI) between January, 14th 2016 and July, 26th 2017, and/or if you purchased Intellipharmaceutics International Inc. (NASDAQ: IPCI) shares in January 2016 or earlier and currently hold any of those shares, you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Intellipharmaceutics International Inc.
Date Filed:July, 28th 2017
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Intellipharmaceutics is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's main product candidate is Rexista, an abuse-deterrent oxycodone hydrochloride extended release tablets. Rexista is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The Complaint alleges the Company made materially false and/or misleading statements regarding its New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") seeking authorization to market its Rexista product.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Intellipharmaceutics International Inc.

First Identified Complaint

Shawn Shanawaz, et al. v. Intellipharmaceutics International Inc., et al.

Date Filed:July, 28th 2017
Class Period Start:January, 14th 2016
Class Period End:July, 26th 2017
First Identified Complaint Filings
#Document TitleFiling Date